Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Canakinumab Injection Clear all
Completed Phase 2 Interventional Results available

To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee

NCT01160822
View directory record Official record
Conditions
Osteoarthritis
Interventions
Canakinumab, Placebo to canakinumab, Naproxen, Placebo to Naproxen
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Anniston, Alabama • Mesa, Arizona • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 19, 2026, 9:09 AM EDT
Terminated Phase 1 Interventional

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

NCT03742349
View directory record Official record
Conditions
Triple Negative Breast Cancer (TNBC)
Interventions
spartalizumab, LAG525, NIR178, capmatinib, MCS110, canakinumab
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

NCT02059291
View directory record Official record
Conditions
Hereditary Periodic Fevers
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 2 Interventional Results available

Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes

NCT00947427
View directory record Official record
Conditions
Type 1 Diabetes, Preservation of Insulin Secretion, Newly Diagnosed Type 1 Diabetes, Canakinumab in Type 1 Diabetes
Interventions
canakinumab (anti IL-1beta), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 45 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
San Francisco, California • Stanford, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 19, 2026, 9:09 AM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)

NCT04814368
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
canakinumab, LNA043, Placebo to canakinumab
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
La Mesa, California • Clearwater, Florida • Sunrise, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 19, 2026, 9:09 AM EDT
Terminated Phase 1 Interventional

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

NCT03064854
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
PDR001, Cisplatin, Gemcitabine, Pemetrexed, Carboplatin, Paclitaxel, Canakinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Fayetteville, Arkansas • Santa Monica, California • Stanford, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients

NCT04581343
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine
Drug
Lead sponsor
Pancreatic Cancer Action Network
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 19, 2026, 9:09 AM EDT
Active, not recruiting Phase 1 Interventional

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

NCT05984602
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Canakinumab, Tislelizumab, Nab-Paclitaxel, Gemcitabine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 1 Interventional

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

NCT02900664
View directory record Official record
Conditions
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Interventions
PDR001, ACZ885, CJM112, TMT212, EGF816
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 19, 2026, 9:09 AM EDT
Recruiting Phase 2 Interventional

Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

NCT06691217
View directory record Official record
Conditions
Vascular Inflammation, ASCVD, ASCVD Management
Interventions
CANAKINUMAB (ILARIS®), Saline (NaCl 0,9 %) (placebo)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis

NCT00424346
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
12
States / cities
Anniston, Alabama • Birmingham, Alabama • Peoria, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 19, 2026, 9:09 AM EDT
Terminated Phase 3 Interventional Results available

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

NCT03631199
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
canakinumab, canakinumab-matching placebo, pembrolizumab, carboplatin, cisplatin, paclitaxel, nab-paclitaxel, pemetrexed
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Long Beach, California • Los Angeles, California • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 19, 2026, 9:09 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

NCT04798339
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Canakinumab Injection, Darbepoetin Alfa
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 2 Interventional Results available

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

NCT01068860
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Canakinumab 150 mg, Placebo to Canakinumab
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2011 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 3 Interventional Results available

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.

NCT01080131
View directory record Official record
Conditions
Acute Gout
Interventions
Canakinumab 150 mg, Triamcinolone acetonide 40 mg, Placebo to canakinumab, Placebo to triamcinolone acetonide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
96
States / cities
Anniston, Alabama • Birmingham, Alabama • Foley, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Oct 19, 2026, 9:09 AM EDT
Terminated Phase 2 Interventional Results available

This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.

NCT03968419
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Canakinumab, Pembrolizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
La Jolla, California • Kansas City, Kansas • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 19, 2026, 9:09 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Canakinumab in Patients With Myelofibrosis

NCT05467800
View directory record Official record
Conditions
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF, Post-polycythemia Vera Related Myelofibrosis, PV-MF
Interventions
Canakinumab
Drug
Lead sponsor
John Mascarenhas
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Tampa, Florida • Westwood, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 3 Interventional Results available

Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

NCT00889863
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis With Active Flare
Interventions
canakinumab, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 19 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Oct 19, 2026, 9:09 AM EDT
Terminated Phase 3 Interventional Results available

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)

NCT00886769
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 19 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 19, 2026, 9:09 AM EDT
Terminated Phase 3 Interventional Results available

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

NCT03447769
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
21
States / cities
Fayetteville, Arkansas • Los Alamitos, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 4 Interventional

COVID-19 VaccinE Response in Rheumatology Patients

NCT05080218
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
Interventions
Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab
Drug
Lead sponsor
Jeffrey Curtis
Other
Eligibility
18 Years to 85 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 2 Interventional Results available

Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk

NCT02272946
View directory record Official record
Conditions
HIV, Cardiovascular Disease
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Priscilla Hsue, MD
Other
Eligibility
40 Years to 59 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

NCT00819585
View directory record Official record
Conditions
Gout
Interventions
Canakinumab, Colchicine, Allopurinol, Placebo Matching Canakinumab, Placebo Matching Colchicine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Huntington Beach, California • San Diego, California • Jupiter, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 19, 2026, 9:09 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

NCT00900146
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canakinumab, Metformin, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
18
States / cities
Phoenix, Arizona • La Jolla, California • Los Gatos, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Oct 19, 2026, 9:09 AM EDT